002294 信立泰
已收盘 07-10 15:00:00
资讯
新帖
简况
7月10日信立泰涨5.45%，中欧医疗健康混合A基金重仓该股
证券之星 · 07-10 16:29
7月10日信立泰涨5.45%，中欧医疗健康混合A基金重仓该股
信立泰（002294）披露SAL0167获得临床试验批准通知书，7月8日股价下跌7.0%
证券之星 · 07-08 22:05
信立泰（002294）披露SAL0167获得临床试验批准通知书，7月8日股价下跌7.0%
信立泰(002294.SZ)：SAL0167获得临床试验批准
智通财经网 · 07-08 16:23
信立泰(002294.SZ)：SAL0167获得临床试验批准
信立泰（002294）披露股票交易异常波动公告，7月3日股价上涨9.99%
证券之星 · 07-03
信立泰（002294）披露股票交易异常波动公告，7月3日股价上涨9.99%
信立泰（002294）披露回购公司股份进展公告，7月1日股价上涨7.24%
证券之星 · 07-01
信立泰（002294）披露回购公司股份进展公告，7月1日股价上涨7.24%
7月1日信立泰涨7.24%，中欧医疗健康混合A基金重仓该股
证券之星 · 07-01
7月1日信立泰涨7.24%，中欧医疗健康混合A基金重仓该股
每周股票复盘：信立泰（002294）首次回购股份999,600股
证券之星 · 06-21
每周股票复盘：信立泰（002294）首次回购股份999,600股
百亿基金经理调仓路径出炉：张坤增聘共管后新布局，葛兰谢治宇反向操作
澎湃新闻 · 06-18
百亿基金经理调仓路径出炉：张坤增聘共管后新布局，葛兰谢治宇反向操作
信立泰（002294）披露首次回购公司股份公告，6月17日股价下跌0.63%
证券之星 · 06-17
信立泰（002294）披露首次回购公司股份公告，6月17日股价下跌0.63%
信立泰最新公告：取得招商银行不超4.5亿元股票回购专项贷款承诺函
证券之星 · 06-10
信立泰最新公告：取得招商银行不超4.5亿元股票回购专项贷款承诺函
信立泰最新公告：拟以3亿元至5亿元回购公司股份
证券之星 · 06-01
信立泰最新公告：拟以3亿元至5亿元回购公司股份
信立泰（002294）股东信立泰药业有限公司质押1500万股，占总股本1.35%
证券之星 · 05-30
信立泰（002294）股东信立泰药业有限公司质押1500万股，占总股本1.35%
信立泰（002294）披露控股股东部分股份解除质押公告，5月22日股价下跌2.62%
证券之星 · 05-22
信立泰（002294）披露控股股东部分股份解除质押公告，5月22日股价下跌2.62%
信立泰(002294.SZ)：SAL0195注射液临床试验申请获受理
智通财经网 · 05-21
信立泰(002294.SZ)：SAL0195注射液临床试验申请获受理
信立泰（002294）披露2025年年度权益分派实施公告，5月18日股价下跌1.39%
证券之星 · 05-18
信立泰（002294）披露2025年年度权益分派实施公告，5月18日股价下跌1.39%
信立泰最新公告：注射用重组特立帕肽获药品注册证书
证券之星 · 05-15
信立泰最新公告：注射用重组特立帕肽获药品注册证书
信立泰（002294）披露第三期员工持股计划第二个锁定期延长公告，5月14日股价下跌3.67%
证券之星 · 05-14
信立泰（002294）披露第三期员工持股计划第二个锁定期延长公告，5月14日股价下跌3.67%
信立泰（002294）披露股票交易异常波动公告，5月13日股价下跌2.96%
证券之星 · 05-13
信立泰（002294）披露股票交易异常波动公告，5月13日股价下跌2.96%
信立泰最新公告：股价异动不涉及未披露重大事项
证券之星 · 05-12
信立泰最新公告：股价异动不涉及未披露重大事项
异动快报：信立泰（002294）5月12日10点44分触及跌停板
证券之星 · 05-12
异动快报：信立泰（002294）5月12日10点44分触及跌停板
加载更多
公司概况
公司名称：
深圳信立泰药业股份有限公司
所属行业：
医药制造业
上市日期：
2009-09-10
主营业务：
深圳信立泰药业股份有限公司的主营业务是药品、医疗器械产品的研发、生产、销售，以及专利授权许可。公司的主要产品是心脑血管、肾脏、代谢类药物、医疗器械、骨科药物、头孢类抗生素、原料。截至报告期末，累计获得有效专利授权392项，其中境外授权（含港澳台地区）83项；正在申请566项，其中境外申请266项，PCT国际申请46项。
发行价格：
41.98
{"stockData":{"symbol":"002294","market":"SZ","secType":"STK","nameCN":"信立泰","latestPrice":37.13,"timestamp":1783666986000,"preClose":35.21,"halted":0,"volume":56314289,"delay":0,"changeRate":0.0545,"floatShares":1115000000,"shares":1115000000,"eps":0.6068,"marketStatus":"已收盘","change":1.92,"latestTime":"07-10 15:00:00","open":34.56,"high":38.51,"low":34,"amount":2059000000,"amplitude":0.1281,"askPrice":37.13,"askSize":410,"bidPrice":37.12,"bidSize":238,"shortable":0,"etf":0,"ttmEps":0.6068,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1783906200000},"marketStatusCode":5,"adr":0,"adjPreClose":35.21,"symbolType":"stock","openAndCloseTimeList":[[1783647000000,1783654200000],[1783659600000,1783666800000]],"highLimit":38.73,"lowLimit":31.69,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":1114816535,"isCdr":false,"pbRate":4.29,"roa":"--","peRate":61.189848,"roe":"2.49%","epsLYR":0.58,"committee":0.345223,"marketValue":41393000000,"turnoverRate":0.0505,"status":0,"nextConnectDate":"根据港交所公布的数据，今日已停止北向交易，下一个交易日为北京时间 2026-07-13。","floatMarketCap":41384000000},"requestUrl":"/m/hq/s/002294","defaultTab":"news","newsList":[{"id":"2650183464","title":"7月10日信立泰涨5.45%，中欧医疗健康混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2650183464","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2650183464?lang=zh_cn&edition=full","pubTime":"2026-07-10 16:29","pubTimestamp":1783672188,"startTime":"0","endTime":"0","summary":"证券之星消息，7月10日信立泰涨5.45%，收盘报37.13元，换手率5.05%，成交量56.31万手，成交额20.59亿元。根据2026基金Q1季报公募基金重仓股数据，重仓该股的公募基金共136家，其中持有数量最多的公募基金为中欧基金的中欧医疗健康混合A。中欧医疗健康混合A目前规模为129.74亿元，最新净值1.8973，较上一交易日上涨2.81%，近一年上涨9.4%。中欧医疗健康混合A的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071000029050.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0187","159760","002294","BK0183","BK0028","BK0239","BK0196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649991432","title":"信立泰（002294）披露SAL0167获得临床试验批准通知书，7月8日股价下跌7.0%","url":"https://stock-news.laohu8.com/highlight/detail?id=2649991432","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2649991432?lang=zh_cn&edition=full","pubTime":"2026-07-08 22:05","pubTimestamp":1783519517,"startTime":"0","endTime":"0","summary":"截至2026年7月8日收盘，信立泰报收于36.0元，较前一交易日下跌7.0%，最新总市值为401.33亿元。该股当日开盘38.02元，最高38.85元，最低35.8元，成交额达17.84亿元，换手率为4.32%。近日，深圳信立泰药业股份有限公司收到国家药品监督管理局核准签发的《临床试验批准通知书》，同意公司自主研发的创新药物SAL0167片开展高脂血症的临床试验。公司将按相关规定开展临床试验，后续进展将及时披露。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070800042521.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0183","002294","BK0187","BK0188","BK0028","BK0196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649969129","title":"信立泰(002294.SZ)：SAL0167获得临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2649969129","media":"智通财经网","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2649969129?lang=zh_cn&edition=full","pubTime":"2026-07-08 16:23","pubTimestamp":1783499036,"startTime":"0","endTime":"0","summary":"智通财经APP讯， 信立泰 发布公告，公司收到国家药品监督管理局核准签发的《临床试验批准通知书》，同意公司自主研发的创新药物SAL0167片开展高脂血症的临床试验。SAL0167是公司具有自主知识产权的环肽药物。环肽具有对靶点的高亲和力和特异性，使SAL0167具备成为需要强效降脂的高胆固醇血症患者的优选方案的潜力。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1464669.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["IBBQ","BK0196","BK0239","BMED","BK0187","002294","BK0028","BK0188","BK0183"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648661312","title":"信立泰（002294）披露股票交易异常波动公告，7月3日股价上涨9.99%","url":"https://stock-news.laohu8.com/highlight/detail?id=2648661312","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2648661312?lang=zh_cn&edition=full","pubTime":"2026-07-03 22:02","pubTimestamp":1783087331,"startTime":"0","endTime":"0","summary":"截至2026年7月3日收盘，信立泰报收于40.08元，较前一交易日上涨9.99%，最新总市值为446.82亿元。近日，信立泰发布《股票交易异常波动公告》。公告显示，公司股票在2026年7月1日至7月3日连续三个交易日内日收盘价格涨幅偏离值累计超过20%，构成股票交易异常波动。公司、控股股东及实际控制人均不存在应披露而未披露的重大事项，且在股票异常波动期间未买卖公司股票。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070300045112.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0239","002294","BK0183","BK0196","BK0028","BK0187"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648654941","title":"信立泰（002294）披露回购公司股份进展公告，7月1日股价上涨7.24%","url":"https://stock-news.laohu8.com/highlight/detail?id=2648654941","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2648654941?lang=zh_cn&edition=full","pubTime":"2026-07-01 22:10","pubTimestamp":1782915028,"startTime":"0","endTime":"0","summary":"截至2026年7月1日收盘，信立泰报收于34.2元，较前一交易日上涨7.24%，最新总市值为381.27亿元。近日，深圳信立泰药业股份有限公司披露《关于回购公司股份的进展公告》。公告显示，公司于2026年5月29日召开董事会，审议通过回购公司股份的议案，拟以自有资金及自筹资金回购A股股份，总金额不低于30,000万元且不超过50,000万元，回购价格不超过45元/股。本次回购符合相关法规及既定方案，后续将根据市场情况继续实施。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070100043322.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002294","BK0239","BK0183","BK0188","BK0187","BK0028","BK0196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648516580","title":"7月1日信立泰涨7.24%，中欧医疗健康混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2648516580","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2648516580?lang=zh_cn&edition=full","pubTime":"2026-07-01 16:46","pubTimestamp":1782895600,"startTime":"0","endTime":"0","summary":"证券之星消息，7月1日信立泰涨7.24%，收盘报34.2元，换手率4.27%，成交量47.56万手，成交额15.69亿元。根据2026基金Q1季报公募基金重仓股数据，重仓该股的公募基金共136家，其中持有数量最多的公募基金为中欧基金的中欧医疗健康混合A。中欧医疗健康混合A目前规模为129.74亿元，最新净值1.8421，较上一交易日下跌0.29%，近一年上涨8.43%。中欧医疗健康混合A的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070100031474.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0239","BK0187","002294","BK0183","159760","BK0188","BK0196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645095736","title":"每周股票复盘：信立泰（002294）首次回购股份999,600股","url":"https://stock-news.laohu8.com/highlight/detail?id=2645095736","media":"证券之星","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645095736?lang=zh_cn&edition=full","pubTime":"2026-06-21 02:18","pubTimestamp":1781979491,"startTime":"0","endTime":"0","summary":"截至2026年6月18日收盘，信立泰报收于30.38元，较上周的31.3元下跌2.94%。本周，信立泰6月15日盘中最高价报31.9元。6月17日盘中最低价报29.85元，股价触及近一年最低点。信立泰当前最新总市值338.68亿元，在化学制药板块市值排名10/150，在两市A股市值排名633/5206。本次回购符合公司既定的回购方案及相关法律法规要求。回购股份将用于后期实施股权激励或员工持股计划。公司后续将根据市场情况在回购期限内继续实施回购计划，并及时履行信息披露义务。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062100000591.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0187","002294","BK0239","BK0196","BK0188","BK0183"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644703956","title":"百亿基金经理调仓路径出炉：张坤增聘共管后新布局，葛兰谢治宇反向操作","url":"https://stock-news.laohu8.com/highlight/detail?id=2644703956","media":"澎湃新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2644703956?lang=zh_cn&edition=full","pubTime":"2026-06-18 15:50","pubTimestamp":1781769000,"startTime":"0","endTime":"0","summary":"随着近期上市公司股东名单密集披露，百亿基金经理二季度调仓路径逐渐清晰。具体来看，易方达基金张坤的代表作基金——易方达蓝筹精选，在增聘基金经理杨思亮、何一铖共管后，首次建仓广深铁路。与此同时，中欧基金葛兰与兴证全球基金谢治宇在泰格医药上反向而行；景顺长城基金刘彦春与大成基金徐彦对晨光股份的调仓路径同样彼此背离，永赢基金高楠则对嘉益股份进行了微调。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202606183776128689.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202606183776128689.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0077","300347","LU1146622755.USD","BK0028","LU1820825898.SGD","BK0187","BK1141","002294","BK1576","BK0239","BK1583","BK0196","BK0216","BK0174","BK0188","03347","BK0183"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644674216","title":"信立泰（002294）披露首次回购公司股份公告，6月17日股价下跌0.63%","url":"https://stock-news.laohu8.com/highlight/detail?id=2644674216","media":"证券之星","labels":["buyback"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2644674216?lang=zh_cn&edition=full","pubTime":"2026-06-17 22:47","pubTimestamp":1781707633,"startTime":"0","endTime":"0","summary":"截至2026年6月17日收盘，信立泰报收于30.16元，较前一交易日下跌0.63%，最新总市值为336.23亿元。该股当日开盘30.21元，最高30.24元，最低29.85元，成交额达4.11亿元，换手率为1.23%。近日，深圳信立泰药业股份有限公司发布《关于首次回购公司股份的公告》。本次回购符合公司既定的回购方案及相关法律法规要求。回购股份将用于后期实施股权激励或员工持股计划。公司后续将根据市场情况在回购期限内继续实施回购计划，并及时履行信息披露义务。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026061700042464.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"buyback","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0183","002294","BK0187","BK0188","BK0028","BK0196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642144088","title":"信立泰最新公告：取得招商银行不超4.5亿元股票回购专项贷款承诺函","url":"https://stock-news.laohu8.com/highlight/detail?id=2642144088","media":"证券之星","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642144088?lang=zh_cn&edition=full","pubTime":"2026-06-10 18:20","pubTimestamp":1781086811,"startTime":"0","endTime":"0","summary":"信立泰(002294.SZ)公告称，公司近日取得招商银行深圳分行《贷款承诺函》，同意为公司回购股份提供不超过4.5亿元的专项贷款，贷款期限36个月，专项用于回购上市公司股票。本次回购资金总金额不低于3亿元，不超过5亿元，回购价格不超过45元/股，回购股份将用于股权激励或员工持股计划。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。相关 ETF","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026061000032714.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU0384037296.USD","SG9999001903.USD","LU1023057109.AUD","LU0543330566.HKD","LU1794554557.SGD","03143","LU0348788117.USD","BK0183","IE00B29SXG58.USD","LU2328871848.SGD","LU0029874905.USD","LU0823426308.USD","LU0463099449.HKD","002294","LU0431992006.USD","LU1366334651.USD","LU0047713382.USD","SG9999002463.SGD","IE00B031HY20.USD","LU0128522744.USD","LU0314109678.HKD","LU0516422440.USD","LU1366334578.USD","LU1064130708.USD","LU1242518931.SGD","LU1064131003.USD","LU2242644610.SGD","LU2148510915.USD","BK0012","LU2226246903.HKD","IE0031814852.USD","LU0501845795.SGD","LU1303224171.USD","IE00BGHQDM52.EUR","BK0010","LU0880133367.SGD","BK0196","LU1008478684.HKD","03968","LU0307460666.USD","LU0821914370.USD","LU0348827113.USD","LU1969619763.USD","LU0708995583.HKD","BK0239","LU0173614495.USD","LU2097828714.EUR","LU0589944569.HKD","600036","IE00BZ08YS42.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640405955","title":"信立泰最新公告：拟以3亿元至5亿元回购公司股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2640405955","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640405955?lang=zh_cn&edition=full","pubTime":"2026-06-01 19:01","pubTimestamp":1780311694,"startTime":"0","endTime":"0","summary":"信立泰(002294.SZ)公告称，公司董事会审议通过回购股份议案，拟以自有资金及自筹资金，通过集中竞价方式回购公司股份，回购资金总额不低于3亿元(含)，不超过5亿元(含)，回购价格不超过45元/股。回购股份将用于后期实施股权激励或员工持股计划，回购期限自董事会审议通过之日起不超过12个月。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。相关 ETF","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026060100033169.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0239","BK0187","002294","BK0188","BK0183","BK0196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639590671","title":"信立泰（002294）股东信立泰药业有限公司质押1500万股，占总股本1.35%","url":"https://stock-news.laohu8.com/highlight/detail?id=2639590671","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2639590671?lang=zh_cn&edition=full","pubTime":"2026-05-30 00:16","pubTimestamp":1780071391,"startTime":"0","endTime":"0","summary":"证券之星消息，信立泰5月30日公开信息显示，股东信立泰药业有限公司向集友银行有限公司合计质押1500.0万股，占总股本1.35%。质押详情见下表：截止本公告日，股东信立泰药业有限公司已累计质押股份4800.0万股，占其持股总数的7.56%。信立泰主营业务：药品、医疗器械产品的研发、生产、销售。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026053000000155.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002294","BK0187","BK0028","BK0239","BK0188","BK0183","BK0196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637310539","title":"信立泰（002294）披露控股股东部分股份解除质押公告，5月22日股价下跌2.62%","url":"https://stock-news.laohu8.com/highlight/detail?id=2637310539","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2637310539?lang=zh_cn&edition=full","pubTime":"2026-05-22 22:04","pubTimestamp":1779458668,"startTime":"0","endTime":"0","summary":"截至2026年5月22日收盘，信立泰报收于35.35元，较前一交易日下跌2.62%，最新总市值为394.09亿元。近日，信立泰发布《关于控股股东部分股份解除质押的公告》。公告显示，公司控股股东信立泰药业有限公司于2026年5月21日解除质押1,600万股公司股份，占其所持股份比例2.52%，占公司总股本比例1.44%，质权人为澳门国际银行股份有限公司。本次解除质押后，其累计被质押股份数量为3,800万股，占其持股总数5.98%，占公司总股本3.41%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052200044749.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0187","BK0183","BK0239","002294","BK0028","BK0188","BK0196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637610383","title":"信立泰(002294.SZ)：SAL0195注射液临床试验申请获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2637610383","media":"智通财经网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2637610383?lang=zh_cn&edition=full","pubTime":"2026-05-21 16:08","pubTimestamp":1779350889,"startTime":"0","endTime":"0","summary":"智通财经APP讯，信立泰 发布公告，近日，公司收到国家药品监督管理局核准签发的受理通知书，公司自主研发的创新siRNA药物SAL0195注射液临床试验申请获得受理。公告显示，SAL0195是基于血脂靶点设计的高活性、高特异性的siRNA药物，在临床前猴模型中具有单次给药即可持续140天的靶点敲除长效作用。若能研发成功并获批上市，将有望为高血脂患者提供新的用药选择，满足未被满足的临床需求，并进一步丰富公司慢病领域的创新产品管线。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1444453.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"信立泰(002294.SZ)：SAL0195注射液临床试验申请获受理","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK0028","BK0196","BK0183","002294","BK0188","BK0187","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636071239","title":"信立泰（002294）披露2025年年度权益分派实施公告，5月18日股价下跌1.39%","url":"https://stock-news.laohu8.com/highlight/detail?id=2636071239","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636071239?lang=zh_cn&edition=full","pubTime":"2026-05-18 22:10","pubTimestamp":1779113424,"startTime":"0","endTime":"0","summary":"截至2026年5月18日收盘，信立泰报收于34.76元，较前一交易日下跌1.39%，最新总市值为387.51亿元。该股当日开盘35.15元，最高35.35元，最低34.48元，成交额达7.21亿元，换手率为1.86%。近日，信立泰发布《2025年年度权益分派实施公告》。公告显示，公司2025年年度权益分派方案已获2026年5月11日召开的年度股东会审议通过。股权登记日为2026年5月25日，除权除息日为2026年5月26日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051800037161.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0183","BK0239","BK0187","BK0028","BK0196","BK0188","002294"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635004407","title":"信立泰最新公告：注射用重组特立帕肽获药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2635004407","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635004407?lang=zh_cn&edition=full","pubTime":"2026-05-15 17:40","pubTimestamp":1778838058,"startTime":"0","endTime":"0","summary":"信立泰(002294.SZ)公告称，公司全资子公司信立泰(苏州)药业有限公司收到国家药品监督管理局核准签发的注射用重组特立帕肽(欣复泰Plus)药品注册证书。该药品适用于有骨折高发风险的绝经后妇女骨质疏松症的治疗，是国内首个上市的特立帕肽周制剂，目前国内尚无同规格及用法用量的产品上市。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。相关 ETF","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051500034157.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002294","BK0028","BK0188","BK0239","BK0196","BK0183","BK0187"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635790171","title":"信立泰（002294）披露第三期员工持股计划第二个锁定期延长公告，5月14日股价下跌3.67%","url":"https://stock-news.laohu8.com/highlight/detail?id=2635790171","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635790171?lang=zh_cn&edition=full","pubTime":"2026-05-14 17:28","pubTimestamp":1778750920,"startTime":"0","endTime":"0","summary":"公司于近日披露《关于第三期员工持股计划第二个锁定期延长的公告》。公告显示，深圳信立泰药业股份有限公司第三期员工持股计划召开持有人会议，基于对公司未来发展前景的信心，同意自愿延长第二个锁定期12个月，由原定的2026年7月12日顺延至2027年7月12日。员工持股计划股份来源于公司回购股份，已于2024年7月10日完成非交易过户，合计23,457,523股，占总股本2.10%。截至目前，第一期已解锁并出售部分股份，当前持股11,728,848股，占总股本1.05%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051400030459.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0028","BK0196","BK0187","BK0183","BK0239","002294"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635420754","title":"信立泰（002294）披露股票交易异常波动公告，5月13日股价下跌2.96%","url":"https://stock-news.laohu8.com/highlight/detail?id=2635420754","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635420754?lang=zh_cn&edition=full","pubTime":"2026-05-13 17:25","pubTimestamp":1778664345,"startTime":"0","endTime":"0","summary":"截至2026年5月13日收盘，信立泰报收于37.65元，较前一交易日下跌2.96%，最新总市值为419.73亿元。该股当日开盘38.8元，最高39.1元，最低37.5元，成交额达19.96亿元，换手率为4.72%。深圳信立泰药业股份有限公司于2026年5月13日发布《股票交易异常波动公告》。公告显示，公司股票在2026年5月8日、5月11日、5月12日连续三个交易日内日收盘价格跌幅偏离值累计超过20%，构成股票交易异常波动。控股股东及实际控制人在异常波动期间未买卖公司股票。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051300031610.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002294","BK0187","BK0028","BK0239","BK0188","BK0183","BK0196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634866297","title":"信立泰最新公告：股价异动不涉及未披露重大事项","url":"https://stock-news.laohu8.com/highlight/detail?id=2634866297","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2634866297?lang=zh_cn&edition=full","pubTime":"2026-05-12 18:00","pubTimestamp":1778580036,"startTime":"0","endTime":"0","summary":"信立泰公告称，公司股票连续三个交易日内日收盘价格跌幅偏离值累计超过20%，属于股票交易异常波动。经自查，公司前期披露信息无需更正补充，未发现公共传媒报道未公开重大信息，目前经营状况良好，外部环境、行业政策及基本面未发生重大变化。公司、控股股东及实际控制人不存在应披露而未披露的重大事项，控股股东、实际控制人在异常波动期间未买卖公司股票。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051200030735.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002294","BK0187","BK0239","BK0188","BK0028","BK0196","BK0183"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634250932","title":"异动快报：信立泰（002294）5月12日10点44分触及跌停板","url":"https://stock-news.laohu8.com/highlight/detail?id=2634250932","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2634250932?lang=zh_cn&edition=full","pubTime":"2026-05-12 10:45","pubTimestamp":1778553926,"startTime":"0","endTime":"0","summary":"证券之星5月12日盘中消息，10点44分信立泰（002294）触及跌停板。其所属行业化学制药目前下跌。领涨股为尔康制药。该股为创新药，化学原料药，健康中国概念热股。5月11日的资金流向数据方面，主力资金净流出2.36亿元，占总成交额41.43%，游资资金净流入9821.96万元，占总成交额17.26%，散户资金净流入1.38亿元，占总成交额24.17%。近5日资金流向一览见下表：信立泰主要指标及行业内排名如下：以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051200013613.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0183","002294","BK0188","BK0239","BK0028","BK0187","BK0196"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1783719985696,"stockEarnings":[{"period":"1week","weight":-0.0736},{"period":"1month","weight":0.187},{"period":"3month","weight":-0.4004},{"period":"6month","weight":-0.3098},{"period":"1year","weight":-0.166},{"period":"ytd","weight":-0.2386}],"compareEarnings":[{"period":"1week","weight":-0.0117},{"period":"1month","weight":0.0007},{"period":"3month","weight":0.0025},{"period":"6month","weight":-0.0302},{"period":"1year","weight":0.1386},{"period":"ytd","weight":0.0069}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"深圳信立泰药业股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"25382人(较上一季度减少3.96%)","perCapita":"43911股","listingDate":"2009-09-10","address":"广东省深圳市福田区福保街道福保社区红柳道2号289数字半岛4层A区","registeredCapital":"111481万元","survey":" 深圳信立泰药业股份有限公司的主营业务是药品、医疗器械产品的研发、生产、销售，以及专利授权许可。公司的主要产品是心脑血管、肾脏、代谢类药物、医疗器械、骨科药物、头孢类抗生素、原料。截至报告期末，累计获得有效专利授权392项，其中境外授权（含港澳台地区）83项；正在申请566项，其中境外申请266项，PCT国际申请46项。","listedPrice":41.98},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"信立泰(002294)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供信立泰(002294)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"信立泰,002294,信立泰股票,信立泰股票老虎,信立泰股票老虎国际,信立泰行情,信立泰股票行情,信立泰股价,信立泰股市,信立泰股票价格,信立泰股票交易,信立泰股票购买,信立泰股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"信立泰(002294)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供信立泰(002294)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}